MAPT and Alzheimer disease: CD2AP is a risk factor for AD, and its abnormalities may be involved in the disease at multiple levels, including affecting the transport and degradation processes of amyloid precursor protein (APP) (26), which influences Aβ production and deposition; participating in Tau protein-mediated neurotoxicity (27); interfering with synaptic function and vesicle release; and affecting the integrity of the blood-brain barrier (28).